Matching articles for "anthracycline"
Issue 1750 · March 16, 2026
Ziftomenib (Komzifti) for Acute Myeloid Leukemia (online only)

Ziftomenib ( Komzifti – Kura), an oral menin inhibitor, has been approved by the FDA for treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1)…

Med Lett Drugs Ther. 2026 Mar 16; 68(1750):e48-9 doi:10.58347/tml.2026.1750e
Ziftomenib ( Komzifti – Kura), an oral menin inhibitor, has been approved by the FDA for treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. It is the second oral menin inhibitor to be approved in the US for this indication; revumenib (Revuforj) was approved in October 2025 for use in patients ≥1 year old.
Issue 1687 · October 16, 2023
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)

The FDA has approved the oral kinase inhibitor quizartinib ( Vanflyta – Daiichi Sankyo) for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):e169-70 doi:10.58347/tml.2023.1687d
The FDA has approved the oral kinase inhibitor quizartinib ( Vanflyta – Daiichi Sankyo) for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy in adults with FLT3 internal tandem duplication (ITD)-positive, newly-diagnosed acute myeloid leukemia (AML).
Issue 1275 · December 3, 2007 Free
In Brief: Dexrazoxane for Anthracycline Extravasation

The FDA has approved a new formulation of dexrazoxane (Totect) for treatment of extravasation from intravenous (IV) anthracyclines such as doxorubicin ( Adriamycin , and others). Dexrazoxane has been available…

Med Lett Drugs Ther. 2007 Dec 3; 49(1275):100
The FDA has approved a new formulation of dexrazoxane (Totect) for treatment of extravasation from intravenous (IV) anthracyclines such as doxorubicin ( Adriamycin , and others). Dexrazoxane has been available since 1995 as Zinecard for protection against the cardiac toxicity of anthracyclines (Med Lett Drugs Ther 1995; 37:110) . It is also available generically. The drug’s precise mechanism of action is not known, but anthracyclines are vesicants that bind to DNA and act as oxidizing agents in the presence of iron. Dexrazoxane is a topoisomerase inhibitor, possibly interfering with anthracycline effects on DNA, and is also a potent iron-chelating agent, preventing free-radical formation. In uncontrolled clinical trials, dexrazoxane appears to have prevented severe necrosis that would require surgical debridement (HT Mouridsen et al. Ann Oncol 2007; 18:546. epub) . It is given in a dose of 1000 mg/m 2 (2000 mg maximum) as an IV infusion over 1-2 hours as soon as possible (no later than 6 hours) after extravasation has occurred and again 24 hours later, and then in a dose of 500 mg/m 2 (1000 mg maximum) 48 hours after the first dose. The dose should be reduced by half in patients with a creatinine clearance <40 mL/min. Download U.S. English
Issue 1228 · February 13, 2006
Nelarabine (Arranon) for T-Cell Acute Lymphoblastic Leukemia

Nelarabine ( Arranon - GlaxoSmithKline), a prodrug of the deoxyguanosine analog 9-β-D-arabinofuranosylguanine (ara-G), has been approved by the FDA for treatment of patients with T-cell acute lymphoblastic…

Med Lett Drugs Ther. 2006 Feb 13; 48(1228):14-5
Nelarabine ( Arranon - GlaxoSmithKline), a prodrug of the deoxyguanosine analog 9-β-D-arabinofuranosylguanine (ara-G), has been approved by the FDA for treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to, or has relapsed following, treatment with at least two chemotherapy regimens.